Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL4755059 | 0.88 | LMNA (0.48) | TSHROPRK1EPHX1HPGDBCHE | |
| Acetic Acid SCHEMBL5147236 | 0.80 | ALDH1A1 (0.52) | TSHROPRK1EPHX1BCHESMN1; SMN2 | |
| Bicarbonate SCHEMBL3258777 | 0.76 | CTSK (0.45) | OPRK1EPHX1EPHX2ALDH1A1 | |
| Acetic Acid SCHEMBL3808908 | 0.76 | CTSK (0.45) | OPRK1EPHX1EPHX2ALDH1A1 | |
| Acetic Acid SCHEMBL4754474 | 0.76 | LMNA (0.53) | OPRK1EPHX1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL4347373 | 0.75 | LMNA (0.55) | OPRK1EPHX1HPGDBCHESMN1; SMN2 | |
| SCHEMBL9294007 | 0.75 | KCNA5 (0.49) | OPRK1EPHX1BCHEEPHX2 | |
| SCHEMBL486678 | 0.74 | ALDH1A1 (0.63) | TSHRHPGDALDH1A1LMNA | |
| Bicarbonate SCHEMBL3256726 | 0.74 | LMNA (0.54) | OPRK1EPHX1HPGDBCHESMN1; SMN2 | |
| Acetic Acid SCHEMBL5145744 | 0.74 | LMNA (0.51) | OPRK1EPHX1HPGDBCHESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | ARBOR PHARMACEUTICALS, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2085087-A1 | Prodrugs of gaba analogs, compositions and uses thereof | Xenoport, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | TSHR 2583/4885OPRK1 313/4885EPHX1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.